Retroviruses & Opportunistic Infections ‘99

Katlama C. , Murphy R. , Johnson V. The Atlantic study: a randomized open-label study comparing two protease inhibitors (PI)-sparing strategies versus a standard PI containing regimen. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract 18.

Staszewski S. , Keiser P. , Gathe J. Ziagen/Combivir is equivalent to indinavir/Combivir in antiretroviral therapy naive adults at 24 weeks. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4 1999; Abstract 20.

Tashima K. , Staszewski S. , Stryker R. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks (Study DMP 266-006). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract LB16.

Chun T-W , Carruth L. , Finzi D. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183–188.

Wong J.K. , Hezareh M. , Günthard H.F. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291–1295.

Finzi D. , Hermankova M. , Pierson T. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–1300.

Chun T-W , Stuyver L. , Mizell S.B. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences, USA 1997; 94: 13193–13197.

Wong J. , Günthard H. , Fiscus S. Residual HIV RNA and DNA in lymph node and HIV RNA in genital secretions and in CSF after two years of suppression of viremia in the Merck 035 cohort. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract 6.

Luzuriaga K. Pediatric antiretroviral therapy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract L2.

Prins J. , Jurriaans S. , van Praag R. OKT3 and rhIL-2 in HIV-1 patients on HAART with prolonged suppression of plasma viremia. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract LB6.

Chun T.W. , Engel D. , Mizell S.B. , Ehler L.A. , & Fauci A.S. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. Journal of Experimental Medicine 1998; 188: 83–91.

Deeks S. , Hoh R. , Hanley M.B. T-cell turnover ’ kinetics in patients with a sustained CD4 cell response after experiencing virologic failure of a protease inhibitor-based regimen. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract LB2.

Stoddart C. , Mammano F. , Moreno M. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract 4.

Clark D.R. , Repping S. , Pakker N.G. , Prins J.M. , Danner S.A. , Lange J.M.A. , & Miedema F. T Cell renewal impaired in HIV-1 infected individuals. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract 22.

McCune J. T cell production in HIV disease. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4 1999; Abstract S43.